山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (3): 58-62.doi: 10.6040/j.issn.1671-7554.0.2018.1411
• • 上一篇
刘萍,庄向华,徐敏,张亮,王雪萌,尚攀,郑凤杰,陈诗鸿
LIU Ping, ZHUANG Xianghua, XU Min, ZHANG Liang, WANG Xuemeng, SHANG Pan, ZHENG Fengjie, CHEN Shihong
摘要： 目的 探讨西格列汀在糖尿病周围神经病变(DPN)中的治疗效果。 方法 选取DPN患者36例,给予西格列汀治疗6个月。比较治疗前后血糖、血脂、多伦多临床评分系统(TCSS)评分及神经传导速度(NCV)变化情况。 结果 应用西格列汀治疗24周后,DPN患者空腹血糖及餐后2 h血糖水平下降(P<0.01),糖化血红蛋白水平降低(P<0.001),TCSS评分下降(P<0.001),NCV增加(P<0.001)。 结论 西格列汀治疗可改善DPN患者临床症状及NCV,在DPN的治疗中具有良好的应用价值。
中图分类号:
| [1] 温旭东, 汤玮, 刘志民. 胰高血糖素样肽-1缓解糖尿病周围神经病变的机制研究进展[J].第二军医大学学报, 2011, 32(3):329-333. WEN Xudong, TANG Wei, LIU Zhimin. Glucagon-like peptide-1 alleviating peripheral neuropathy in diabetic patients:advance in mechanism[J]. Academic Journal of Second Military medical University, 2011, 32(3):329-333. [2] Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7):539-553. [3] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1):4-67. [4] 陆游, 陆颖理. 糖尿病性周围神经病变发生机制的研究进展[J]. 上海交通大学学报(医学版), 2017, 37(10):1441-1445. LU You, LU Yingli. Progress in pathogenesis of diabetic peripheral neuropathy[J]. Journal of Shanghai Jiaotong University(Medical Science), 2017, 37(10):1441-1445. [5] Javed S, Alam U, Malik RA. Treating diabetic neuropathy:present strategies and emerging solutions[J]. Rev Diabet Stud, 2015, 12(1/2):63-83. [6] Malik RA. Why are there no good treatments for diabetic neuropathy?[J]. Lancet Diabetes Endocrinol, 2014, 2(8):607-609. [7] Winkler G. Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism[J]. Orv Hetil, 2013, 154(7):248-255. [8] Shen T, Xu BL, Lei T, et al. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway[J]. Exp Ther Med, 2018, 16(4):3121-3128. [9] Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab, 2018, 27(4):740-756. [10] Cai XL, Gao XY, Yang WJ, et al. DPP-4 inhibitor treatment in Chinese type 2 diabetes patients: a meta-analysis[J]. Diabetes Technol Ther, 2016, 18(12):784-793. [11] Hölscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimers disease[J]. Alzheimers Dement, 2014, 10(1 Suppl):S47-S54. [12] Tai JJ, Liu WZ, Li YW, et al. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimers disease[J]. Brain Res, 2018, 1678:64-74. doi:10.1016/j.brainres.2017.10.012. [13] Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration[J]. Vitam Horm, 2010, 84:331-354. doi:10.1016/B978-0-12-381517-0.00013-8. [14] Feng P, Zhang XJ, Li DF, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinsons disease[J]. Neuropharmacology, 2018, 133:385-394. doi:10.1016/j.neuropharm.2018.02.012. [15] Cai XS, Tan ZG, Li JJ, et al. Glucagon-like peptide-1(GLP-1)treatment ameliorates cognitive impairment by attenuating arc expression in type 2 diabetic rats[J]. Med Sci Monit, 2017, 23:4334-4342. doi:10.12659/MSM.903252. [16] Liu WJ, Jin HY, Lee KA, et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats[J]. Br J Pharmacol, 2011, 164(5):1410-1420. [17] Ma JJ, Shi M, Zhang XC, et al. GLP-1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF-κB signaling pathways in streptozotocin-induced diabetic rats[J]. Int J Mol Med, 2018, 41(5):2977-2985. [18] Yang CP, Li CI, Liu CS, et al. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM[J]. Neurology, 2017, 88(10):944-951. [19] Selvarajah D, Wilkinson ID, Maxwell M, et al. Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy[J]. Diabetes Care, 2014, 37(6):1681-1688. [20] Rizzo MR, Barbieri M, Marfella R, et al. Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082[J]. Diabetes Care, 2013, 36(1):e13. doi:10.2337/dc12-1436. [21] 赵亚丽. 2型糖尿病使用西格列汀对氧化应激和炎性反应状态的控制及对周围神经病变的影响[J]. 河北医药, 2017, 39(23):3550-3553. ZHAO Yali. Effects of sitagliptin on oxidative stress, inflammatory reactions and peripheral neuropathy of patients with type 2 diabetes mellitus[J]. Hebei Medical Journal, 2017, 39(23):3550-3553. [22] Heppner KM, Kirigiti M, Secher A, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate(Macaca mulatta)brain[J]. Endocrinology, 2015, 156(1):255-267. [23] 程茅薇, 顾萍, 马健, 等. 西格列汀对db/db糖尿病小鼠坐骨神经传导速度的影响[J]. 中国全科医学, 2011, 14(18):2055-2058. CHENG Maowei, GU Ping, MA Jian, et al. Effects of sitagliptin on motor nerve conduction velocity of sciatic nerve in db/db mice[J]. Chinese General Practice, 2011, 14(18):2055-2058. [24] Gong N, Xiao Q, Zhu B, et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity[J]. J Neurosci, 2014, 34(15):5322-5334. [25] Tani S, Ken NG, Hirayama A. Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study[J]. Am J Cardiovasc Drugs, 2013, 13(6):443-450. [26] Yoon SA, Han BG, Kim SG, et al. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study(the GUARD Study)[J]. Diabetes Obes Metab, 2017, 19(4):590-598. [27] Marques C, Mega C, Gonçalves A, et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals[J]. Mediators Inflamm, 2014:538737. doi:10.1155/2014/538737. |
| [1] | 郑凤杰,宋玉文,孙爱丽,潘喆,王殿辉,娄能俊,吕丽,庄向华,陈诗鸿. 糖尿病周围神经病变与肌少症的关联性[J]. 山东大学学报 (医学版), 2021, 59(6): 38-44. |
| [2] | 张亮,徐敏,庄向华,娄福臣,娄能俊,吕丽,郭文娟,郑凤杰,陈诗鸿. 内质网应激与凋亡在糖尿病周围神经病变中的表达变化[J]. 山东大学学报（医学版）, 2017, 55(8): 13-17. |
| [3] | 彭力,强晔,赵蕙琛,陈诗鸿,姚伟东,刘元涛. 2型糖尿病患者应用西格列汀的短期疗效及影响因素[J]. 山东大学学报（医学版）, 2016, 54(8): 60-63. |
| [4] | 史蕊,孙佩,王璐璐,丁琳,夏金,王燕,逄曙光. 鼠神经生长因子联合维生素D、甲钴胺治疗糖尿病周围神经病变的临床观察[J]. 山东大学学报（医学版）, 2016, 54(4): 64-67. |
| [5] | 孙卓浩, 刘妍, 周冬梅, 李伟. 阿米替林治疗痛性糖尿病周围神经病变的临床研究[J]. 山东大学学报（医学版）, 2015, 53(5): 81-84. |
| [6] | 裴蕾蕾, 孙中华, 李哲, 赵文萍. 西格列汀联合大剂量胰岛素治疗2型糖尿病的临床观察[J]. 山东大学学报（医学版）, 2015, 53(2): 39-42. |
| [7] | 李海素，杨崇美. DPP-4抑制剂治疗小鼠溃疡性结肠炎的疗效[J]. 山东大学学报(医学版), 2013, 51(12): 29-33. |
|
||
